New strategy aims to keep advanced prostate cancer in check longer
NCT ID NCT06734130
Summary
This study is testing whether a flexible, 'adaptive' approach to hormone therapy, combined with a chemotherapy drug called docetaxel, can help men with advanced prostate cancer stay responsive to standard hormone treatments for a longer period. The goal is to delay the cancer's progression and extend the time before more aggressive treatments are needed. The trial is enrolling 25 men whose prostate cancer has spread but still responds to hormone-blocking therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Caner Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.